(BHVN) – Company Press Releases
-
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
-
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
-
Biohaven Announces Proposed Public Offering of Common Shares
-
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
-
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
-
Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therap
-
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting
-
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments
-
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®
-
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
-
Biohaven Announces Pricing of $225 Million Public Offering of Common Shares
-
BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES
-
Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy
-
Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Stu
-
Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy
-
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
-
Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates
-
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
-
Biohaven to Present R&D Day at Yale School of Management
-
Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
-
Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy
-
Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments
-
Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders
-
Biohaven Announces Presentation at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
-
Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy
-
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
-
Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors
-
Jon Soderstrom Joins Wilson Sonsini as Chief Licensing Advisor
-
Biohaven Ltd. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments
-
PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK
-
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
-
Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University
-
Biohaven Announces Pricing of Public Offering of Common Shares
-
Biohaven Announces Launch of Public Offering of Common Shares
-
Biohaven Sets New Course with $258 Million in Cash, a Proven Team and Deep Pipeline to Continue its Journey to Advance Science for Patients
-
Pfizer Completes Acquisition of Biohaven Pharmaceuticals
-
Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial)
-
Biohaven Announces Record Date for Anticipated Spin-Off
-
Real-World Administrative Claims Analysis Demonstrates That Almost Half of Migraine Patients Discontinue Barbiturate Use After Initiation of Nurtec ODT
-
Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments
-
Biohaven Reports Second Quarter 2022 Financial Results and Reports Recent Business Developments
-
American Migraine Foundation Survey Shows Nearly All People with Migraine and Healthcare Professionals Believe Migraine and Mental Health Significantly Impact Each Other
-
Biohaven Enrolls First Patient in Phase 3 Trial of Taldefgrobep alfa in Spinal Muscle Atrophy (SMA)
-
Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial
-
Biohaven Presents New Migraine Data at 64th Annual Scientific Meeting of the American Headache Society, including First of Its Kind Study for Nurtec® ODT (rimegepant), and Complete Phase 3 Data for Z
-
Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American Head
-
US FDA Accepts for Review Biohaven's New Drug Application (NDA) Filing of Intranasal Zavegepant for the Acute Treatment of Migraine
-
Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)
Back to BHVN Stock Lookup
